all report title image
  • Published In : Feb 2024
  • Code : CMI6661
  • Pages :180
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

The global acute dystonia market was valued US$ 120.7 Mn in 2023 and is expected to reach US$ 155.0 Mn by 2031 growing at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

Anticholinergic medications, such as trihexyphenidyl and benzatropine, work by blocking acetylcholine, a chemical messenger in the brain. This helps in reducing the muscle spasms caused by dystonia. However, anticholinergic drugs can cause side effects like blurred vision, constipation, and dry mouth. Benzodiazepines like clonazepam and lorazepam work by enhancing the effect of the inhibitory neurotransmitter, GABA, helping to relieve contractions. While benzodiazepines provide relatively fast relief, their use comes with risks of dependency and withdrawal symptoms on discontinuation.

Other less commonly used treatments include muscle relaxants like baclofen and dantrolene sodium which alter calcium channels in muscles to reduce spasms. Intramuscular injections of botulinum toxin are also given to block muscle activity in specific areas. While these options may provide effective symptom relief, they have disadvantages such as potential for side effects and short-term relief requiring repeated injections.

Global Acute Dystonia Market - Regional Insights

  • North America is expected to be the largest market for acute dystonia during the forecast period, accounting for over 43.7% of the market share in 2023. North America has been dominating the global acute dystonia market for many years due to a strong presence of top pharmaceutical companies and advanced healthcare facilities in the region. The U.S. accounts for the major share due to the growing dystonia patient population and high healthcare expenditure. Several key players have their global headquarters located in the U.S. and invest heavily in R&D of new drugs to treat acute dystonia. This has ensured quicker availability of innovative medicines in the U.S. compared to other countries. Moreover, high reimbursement costs and large healthcare budgets of public and private insurance providers make new drug treatments easily affordable.
  • Asia Pacific is expected to be the second-largest market for acute dystonia market, accounting for over 25.2% of the market share in 2023. The Asia Pacific region has emerged as the fastest growing market for acute dystonia treatment Rapid economic development, rising healthcare investments, and growing medical needs of its huge population are key growth drivers. Countries like China and India have a large number of dystonia patients and are witnessing increased diagnosis rates. At the same time, these markets are much less saturated than developed markets of North America and Europe. This provides huge untapped business opportunities for companies to expand their presence. Additionally, lower manufacturing costs have attracted several large pharmaceutical players to establish production facilities in Asia Pacific. This has made branded drugs more affordable to patients in the region. Meanwhile, exports of generic drugs from India and China are contributing significantly to their growth in the global acute dystonia market.
  • Europe is another prominent region benefiting from increased healthcare spending and universal insurance coverage. Major countries like Germany, U.K. and France are high potential markets where neurological disorders are gradually gaining focus. This has prompted proactive manufacturing and marketing strategies by key industry stakeholders looking to make inroads.

Figure 1. Global Acute Dystonia Market Share (%), By Region, 2024


To learn more about this report, request a free sample copy

Analyst’s Views:

The global acute dystonia market is poised to grow steadily over the next decade. The market is primarily driven by rising awareness about the treatment options for acute dystonia and an increasing number of people suffering from the condition. North America currently dominates the market due to high healthcare expenditure and growing research and development activities for novel drug development in the region. However, Asia Pacific is expected to be the fastest growing market owing to the large patient pool and improving access to healthcare in various countries.

Global Acute Dystonia Market - Drivers

Increasing prevalence of dystonia: The incidence and prevalence of dystonia is on the rise globally. As per various studies and research, dystonia is more common than previously thought with an estimated prevalence of 17.6 per 100,000 people worldwide. The condition is also known to be under-diagnosed in many parts of the world. With growing awareness about different types of dystonia among medical professionals as well as general public, more cases are being identified and reported.

The ageing population across the developed world has also contributed to the increasing prevalence of dystonia. Since dystonia is more likely to develop in older individuals, countries with larger elderly population cohorts have witnessed higher dystonia patient numbers. Rising life expectancy worldwide indicates that the percentage of people struggling with age-related medical issues including dystonia will continue expanding in the future. Additionally, factors like better diagnosis and documentation have made many historic or undiagnosed dystonia cases visible now.

The growing dystonia patient pool is expected to significantly drive the demand for effective treatment options and acute dystonia management drugs. With more dystonia types and subtypes being identified, the market is also witnessing demand for condition-specific drug therapies. Currently available generic drugs may not fully address all manifestations of dystonia phenotypes. This unmet need opens up opportunities for novel drug research and development by pharmaceutical players.

Advancing research on etiology and new drug targets: Considerable research efforts are ongoing in the field of dystonia with focus on improving understanding of underlying pathology and identifying new therapeutic areas. While several causative genetic flaws and likely biochemical irregularities have been linked to certain dystonia types, exact reasons for development and progression of the condition remain ambiguous in majority of cases.

Continued molecular level investigation of dystonia has the potential to uncover novel biological pathways and targets for acute as well as long-term symptomatic relief. Promising areas that are under active study include role of Basal Ganglia circuits, disturbed Dopamine-GABA signaling in the brain, neurological signaling abnormalities triggered by genetic mutations. Advancing knowledge about dystonia etiology can facilitate the creation of precision medicines and assist researchers in repurposing existing drugs for off-label dystonia applications.

In addition, non-dopaminergic treatments are being explored as current therapy options centered around Dopamine agonists have limited efficacy in many patients and produce undesirable side effects. Newer drug classes in preclinical/clinical trial phases include GABA enhancers, glutamate blockers, histone deacetylase inhibitors, and others. Successful research outcomes indicating the safety and effectiveness of investigational compounds can stimulate the demand for improved pharmaceutical interventions apart from standard drug formulations.

The growing research and development focus on novel drug targets and precision therapies presents potential growth opportunities for the acute dystonia market. It may also help address currently unmet needs of subsets of dystonia patients not benefitting from first line medications. This ongoing research renaissance can potentially expand the arsenal of acute dystonia management solutions available to medical community and patients.

Global Acute Dystonia Market - Opportunity

  • Understanding changing treatment patterns: The diagnosis and treatment patterns for acute dystonia are evolving rapidly across major markets. Traditionally, acute dystonia was mainly treated using anticholinergic medications which provide quick relief from dystonic episodes but have strong side effects. However, in recent years there has been a noticeable shift towards the use of botulinum toxin injections as the first line therapy. Botulinum toxin offers targeted treatment to affected muscle groups and provides weeks of relief from symptoms with relatively mild side effects. The success of botulinum toxin in chronic dystonia indications has led many neurologists and patients to prefer it for acute dystonia cases as well. In addition, new guidelines from treatment societies now list botulinum toxin ahead of anticholinergics as the standard of care. This changing treatment paradigm means drug manufacturers need to demonstrate the benefits of alternative therapies like novel oral treatments compared to injections in order to gain usage in acute dystonia patients.

Global Acute Dystonia Market Report Coverage

Report Coverage Details
Base Year: 2023 Market Size in 2023: US$ 120.7 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2024 to 2031 CAGR: 3.2% 2031 Value Projection: US$ 155 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Anticholinergic Agents, Benzodiazepines, Others (Neurotoxin, etc.)
  • By Age Group: Children, Adult
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.

Growth Drivers:
  • Increasing prevalence of dystonia
  • Advancing research on etiology and new drug targets
Restraints & Challenges:
  • Side effects associated with drugs
  • Stringent regulatory frameworks

Global Acute Dystonia Market – Trend

  • Growth in clinical trial activities: The rise in clinical trial activities has influenced the global acute dystonia market positively in recent years. With more awareness about neurological conditions and increased research for finding better treatments, the number of clinical trials for drugs and therapies related to acute dystonia has seen a significant jump globally. Many biopharmaceutical companies and research institutes are actively conducting trials to evaluate new drug entities and treatment mechanisms for acute dystonia. Also the clinical trials have provided insights into disease pathophysiology and aided the development of personalized treatment protocols. Successful trials are also encouraging the approval and global launch of modern treatment alternatives. Overall, the rising clinical research activities indicate continued progress is being made towards improving acute dystonia management. This positive sentiment among medical researchers and patients has been translating into the growing demand for newer treatment choices. It is driving the expansion of the global acute dystonia market in terms of higher investments, innovations, and launch of advanced therapeutics in the healthcare market.

Global Acute Dystonia Market - Restraints

  • Side effects associated with drugs: The occurrence of side effects associated with drugs being prescribed for acute dystonia is a major restraint on the growth of the global acute dystonia market. Acute dystonia commonly manifests as abnormal involuntary muscle contractions which may involve the eyes, torso, limbs, or respiratory muscles. While anticholinergic drugs and benzodiazepines are often prescribed to treat acute dystonia, they have considerable side effect profiles which discourage physicians from prescribing them and patients from taking them. Anticholinergic drugs like benztropine prescribed for acute dystonia treatment causes severe dry mouth in many patients along with other anticholinergic side effects like blurred vision, constipation, and difficulty in urination. These uncomfortable and sometimes serious side effects lead to low compliance among patients. Many tend to discontinue the treatment. This affects the growth of drug prescriptions for acute dystonia negatively. Benzodiazepines another class of drugs prescribed have side effects like drowsiness, dizziness and impaired coordination which can increase falls risks in elderly patients suffering from dystonia. Some patients may also experience mood changes, confusion, and paradoxical aggression upon taking benzodiazepines.
  • Stringent regulatory frameworks: Stringent regulatory norms and guidelines around the approval of drugs for treating acute dystonia has significantly slowed down the growth of this market in recent years. Multiple drug candidates that showed promise in clinical trials have failed to get regulatory approvals or had to face long review periods. For instance, a new drug developed by pharmaceutical company that was found effective in treating acute dystonic reactions received a complete response letter from the U.S. Food and Drug Administration (FDA) in 2021 citing deficiencies in the quality systems and manufacturing processes.
  • Counterbalance – Thus, key market players should form strategic alliances with other providers or healthcare networks to increase the bargaining power of payers and to capitalize on shared resources and ensure that healthcare providers and staff are educated about the latest best practices in documentation and coding, which is essential for maximizing the regulatory guidelines for easy approval procedures.

Figure 2. Global Acute Dystonia Market Share (%), By Drug Class, 2024


To learn more about this report, request a free sample copy

Top Companies in the Global Acute Dystonia Market

  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F.Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.

Definition: Acute dystonia refers to involuntary muscle contractions or spasms that cause abnormal postures of the body. These postures can affect legs, pelvic area, trunk, neck, shoulders, or arms. There are multiple types of acute dystonia seen in clinical practice. The most common types include torticollis, which involves abnormal turning or twisting of the neck, opisthotonus characterized by arching of the back and back bending, and trismus known as lockjaw.

Frequently Asked Questions

Side effects associated with drugs and stringent regulatory frameworks are the key factor hampering the growth of the global acute dystonia market.

Increasing prevalence of dystonia and advancing research on etiology and new drug targets are the major factors driving the global acute dystonia market growth.

The anticholinergic agents segment is the leading drug class segment in the global acute dystonia market.

The major players operating in the global acute dystonia market are Fresenius Kabi, Amar Healthcare, Johnson & Johnson, PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.

North America will lead the global acute dystonia market.

The CAGR of the global acute dystonia market is expected to be 3.2%.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount

Reliability and Reputation

DUNS Registered
DMCA Protected


Reliability and Reputation


Reliability and Reputation


Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo